Managing Severe Sepsis in the ICU The Clinical Synergy of PCT and IL-6 Testing

2026-07-03 |

1. Introduction

Sepsis is a medical emergency in which rapid assessment and repeated reassessment are essential. No single laboratory marker can confirm or exclude sepsis, but complementary biomarkers can add objective information while clinicians evaluate infection, organ dysfunction, microbiology, imaging and source control.

PCT and IL-6 provide different views of the host response. IL-6 reflects early inflammatory activation, while PCT is more closely associated with systemic bacterial infection and often remains elevated longer. Used together and interpreted as trends, they can support a clearer picture of disease evolution in the ICU.

2. Why PCT and IL-6 Work Better Together

The value of combined testing comes from complementary timing and clinical interpretation rather than from a single universal cut-off.

Marker

What it adds

Key limitation

IL-6

Early signal of cytokine-driven inflammation; useful for severity context and rapid change over time.Also valuable in COVID-19 severity stratification and cytokine release syndrome (CRS) monitoring.

Sensitive but not specific for bacterial infection; may rise after surgery, trauma or other inflammatory stress.

PCT

Adds context for systemic bacterial infection and is useful for serial monitoring and antimicrobial review.

May remain low in very early or localized infection and can be influenced by timing, renal dysfunction and major tissue injury.

PCT and IL-6

Practical interpretation Focus on direction of change. A persistent or secondary rise should prompt reassessment for uncontrolled infection, inadequate source control, complications or a non-infectious inflammatory process.

3. A Practical ICU Testing Framework

At presentation

Clinical exam, cultures, lactate, organ-function assessment + baseline PCT and IL-6

6–24 hours

Repeat biomarkers when clinically indicated; focus on direction and rate of change

Ongoing ICU review

Integrate trends with source control, microbiology, hemodynamics and response to therapy

Antibiotic review

Use PCT only with clinical evaluation; never as the sole reason to start or stop treatment

4. Poclight C5000 Assay Information

Assay	Sample	Volume	Time	Measuring range	Storage / stability
PCT	Serum / Plasma	200 µL	5 min	0.02-100 ng/mL	2-30°C / 18 months
IL-6	Serum / Plasma	100 µL	15 min	1.5-5000 pg/mL	2-30°C / 18 months

Our standout features:

1. Small Sample Volume & Rapid Results

Small sample volume of serum or plasma needed, with 5-15 minute turnaround, ideal for fast clinical decisions.

2. Freeze-dried reagents: no cold chain, 18 months shelf life, simplifying storage and transport.

3. High accuracy and excellent precision (CV < 5%)

4. Applicable with the C5000 POC CLIA Analyzer: 3-Step Operation, Maintenance-Free

Monitoring Drug-Induced Lung Injury Expanding the Clinical Application of KL-6

2026-07-03 |

{ POCT Analyzer }
{ C5000 Bench-top CLIA Analyzer }
{ Krebs von den Lungen 6(KL-6) Test Kit }

1. Drug-Induced Lung Injury: A Diagnostic Challenge

Drug-induced lung injury may occur during treatment with anticancer agents, immune checkpoint inhibitors, targeted therapies, disease-modifying antirheumatic drugs, amiodarone and other implicated medicines. Symptoms and imaging patterns can overlap with infection, tumour progression, pulmonary oedema or worsening pre-existing interstitial lung disease (ILD).

Assessment therefore depends on the complete clinical picture: medication exposure and timing, symptoms, oxygenation, high-resolution computed tomography (HRCT), pulmonary function, microbiology and specialist review. KL-6 can add a non-invasive blood-based perspective on alveolar epithelial injury within this wider assessment.

Core message KL-6 is not a drug-specific marker. Its value is greatest when serial results are interpreted together with HRCT, symptoms, pulmonary function and infection-related testing.

2. What KL-6 Reflects

KL-6 is a high-molecular-weight MUC1 glycoprotein mainly expressed by type II alveolar epithelial cells. When epithelial injury, regeneration and alveolar-capillary leakage occur, KL-6 may enter the circulation. This makes it a useful supportive marker for ILD-related assessment and follow-up.

Why KL-6 Can Add Value in Drug-Related Lung Injury Assessment

1. Drug exposure / treatment

Targeted therapy, ICI, chemotherapy, antiarrhythmic, DMARD or other implicated drug

2. Alveolar epithelial injury

Type II pneumocyte injury, regeneration and increased alveolar-capillary permeability

3. KL-6 enters circulation

A blood-based signal reflecting epithelial injury burden—not a drug-specific marker

4. Integrated clinical interpretation

Use with symptoms, HRCT, PFT / DLCO, medication timeline and infection work-up

3. Where KL-6 Adds Clinical Value

Clinical focus	Potential value	How to interpret
Triggered assessment	Adds an epithelial-injury signal when new respiratory symptoms or HRCT changes raise concern for treatment-related ILD.	Integrate with medication timing, oxygenation, HRCT and infection work-up.Elevated KL-6 can assist in the judgment of drug-induced lung injury, especially providing blood-based epithelial injury signals in the differential diagnosis of "abnormal HRCT but unknown etiology"
Dynamic monitoring	Serial change may help show improvement, persistence or progression during follow-up.	Trend direction is generally more informative than one isolated result.
Differential support	Can be combined with PCT, CRP and microbiology when infection and drug-related pneumonitis are both possible.	No biomarker combination replaces imaging, cultures or multidisciplinary review.

4. A Practical Monitoring Pathway

Suggested Monitoring Pathway (Adapt to Local Protocols)

1. Before therapy

Review prior ILD, thoracic radiation, lung function and drug-specific risk.

Consider a baseline KL-6 value when clinically appropriate.

2. During therapy

Track new cough, dyspnea, fever, oxygen saturation or exercise intolerance.

3. When lung injury is suspected

Prompt clinical review, HRCT, infection evaluation, PFT / DLCO when feasible, and KL-6 with complementary markers.

4. Follow-up

Use serial clinical, imaging and functional assessment. KL-6 trend may add context to improvement or progression.

5. KL-6 Testing on the Poclight C5000